KR20240177794A - Composition Comprising Lactobacillus rhamnosus CBT LR6-feminine - Google Patents

Abstract

The present invention relates to a vaginal-derived Lactobacillus rhamnosus CBT LR6-feminine strain. The Lactobacillus rhamnosus CBT LR6-feminine strain of the present invention has excellent lactic acid production ability and hydrogen peroxide production ability, and has antibacterial activity against not only vaginitis-causing bacteria but also urinary tract infection-causing bacteria, and has excellent vaginal adhesiveness, acid resistance, and bile resistance. Therefore, it can be effectively used for the prevention, alleviation, or treatment of vaginitis related to women's health.

Description

Composition comprising Lactobacillus rhamnosus CBT LR6-feminine {Composition Comprising Lactobacillus rhamnosus CBT LR6-feminine}

The present invention relates to a Lactobacillus rhamnosus CBT LR6-feminine strain, and more specifically, to the strain, a killed cell thereof, or a culture thereof, and to an antibacterial composition comprising the same, a pharmaceutical composition for preventing or treating vaginitis, a food composition for preventing or improving vaginitis, and an quasi-drug composition for preventing or improving vaginitis.

Worldwide, 3/4 of the female population suffers from inflammatory female diseases, including bacterial vaginosis, during their lifetime, and 50% of them are reported to experience recurrence. In addition, more than 60% of female vaginitis is asymptomatic infection, and susceptibility to vaginitis increases significantly due to antibiotics, stress, and hormonal changes after menopause.

The vagina is the passage connecting the vulva and the uterus, and is the most moist and warm part of the female body. Therefore, it is a suitable environment for bacteria and fungi, which are the main causes of vaginitis, to grow, and there is a high possibility of disease caused by them. Under normal conditions, many lactic acid bacteria grow inside the vagina, making the inside of the vagina slightly acidic, which inhibits the growth of pathogens and fungi. However, when the balance inside the vagina is disrupted due to long-term use of antibiotics or birth control pills, use of tampons or loops, or changes in the balance of female hormones due to pregnancy, childbirth, breastfeeding, menopause, etc., opportunistic pathogens that normally grow under normal conditions can grow inside the vagina, causing vaginitis. Vaginitis has been reported to include bacterial vaginosis, candidal vaginitis, trichomoniasis, and atrophic vaginitis, but the most common vaginitis is bacterial vaginosis.

Bacterial vaginosis is caused by Gardnerella vaginalis . This vaginitis occurs when the number of lactic acid bacteria residing in the vagina decreases due to an imbalance in vaginal acidity, while anaerobic bacteria, which account for less than 1%, proliferate. The causative factor that causes changes in the normal vaginal flora is unknown, but it is thought that repeated alkalinization of the vagina due to frequent sexual intercourse or vaginal douching plays a role. When the lactic acid bacteria that normally produce hydrogen peroxide disappear, it is difficult to regenerate the normal vaginal flora, so bacterial vaginosis often reoccurs. Additionally, women with bacterial vaginosis have a higher incidence of serious complications, including pelvic inflammatory disease (PID), post-miscarriage PID, postoperative cuff cellulitis, and abnormal cervical cytology, and pregnant women are at risk for premature rupture of membranes, preterm labor, preterm birth, chorioamnionitis, and post-cesarean endometritis.

Candidal vaginitis, a common disease along with bacterial vaginosis, is a disease in which the fungus Candida albicans lives in the moist genital area and causes inflammation. Approximately 75% of women experience vaginal and vulvar candidal vaginitis at least once during their lifetime, and 45% of women experience recurrence more than twice a year. Candida (mainly Candida albicans), which is normally present in the oral cavity, intestines, and vagina of healthy people, can cause infection when the female hormone status is abnormal due to pregnancy or long-term use of oral contraceptives, or when the immune system is extremely weakened due to colds, diabetes, or AIDS. It can also occur due to obesity, antibiotic allergies, or taking adrenal cortex hormones used to treat arthritis. In cases of outbreaks due to antibiotic administration, the antibiotics kill the beneficial lactic acid bacteria in the vagina, and in such cases, the possibility of recurrence is high.

Recently, it has been known that Lactobacilli , which are prevalent in the vagina of women, reduce the risk of bacterial vaginosis. In general, the vagina of a healthy woman is known to be the most important defense mechanism that suppresses the growth of other pathogenic microorganisms by maintaining the pH of the vagina below 4.5 with various types of Lactobacilli colonizing it.

The patent documents and references mentioned in this specification are incorporated by reference into this specification to the same extent as if each document was individually and specifically designated by reference.

Korean Patent Publication No. 10-2022-0164351 (Publication Date; December 13, 2022)

The present inventors have conducted research efforts to develop probiotic lactic acid bacteria strains that can be applied to the prevention, alleviation, and treatment of vaginitis related to women's health. As a result, they developed vaginal lactic acid bacteria with excellent lactic acid production and hydrogen peroxide production abilities, and experimentally verified and confirmed that this lactic acid bacteria has antibacterial activity not only against vaginitis-causing bacteria but also against urinary tract infection-causing bacteria, and has excellent vaginal adhesiveness, acid resistance, and bile resistance, thereby completing the present invention.

Accordingly, the purpose of the present invention is to provide a Lactobacillus rhamnosus CBT LR6-feminine strain deposited under the deposit number KCTC19091P.

Another object of the present invention is to provide a composition comprising at least one selected from the group consisting of the strain, dead cells thereof, and cultures thereof.

Another object of the present invention is to provide an antibacterial composition comprising a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof.

Another object of the present invention is to provide a pharmaceutical composition for preventing or treating vaginitis, comprising (i) a composition comprising at least one selected from the group consisting of the strain, its dead cells and its culture; and (ii) a pharmaceutically acceptable carrier.

Another object of the present invention is to provide a food composition for preventing or improving vaginitis, comprising a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof.

Another object of the present invention is to provide a pharmaceutical composition for preventing or improving vaginitis, comprising a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof.

Other objects and technical features of the present invention are more specifically presented in the detailed description of the invention, the claims and the drawings below.

According to one aspect of the present invention, the present invention provides a Lactobacillus rhamnosus CBT LR6-feminine strain deposited under the deposit number KCTC19091P.

According to one embodiment of the present invention, the strain may comprise a 16S rRNA gene represented by sequence number 1.

According to one embodiment of the present invention, the strain has antibacterial activity against Candida albicans, Gardnerella vaginalis or Escherichia coli .

According to another aspect of the present invention, the present invention provides a composition comprising at least one selected from the group consisting of the strain, dead cells thereof, and cultures thereof.

The term “strain” in the present invention includes not only the live bacteria obtained from the culture medium, but also any processed form known to those skilled in the art, including, but not limited to, dried products, frozen products, and fragments. In addition, the term “culture” includes “fermented products,” and includes processed products derived from the culture solution itself, such as the culture solution cultured in a liquid medium, and the filtrate (centrifuged supernatant) obtained by filtering or centrifuging the culture solution to remove the strain.

According to another aspect of the present invention, an antibacterial composition is provided, comprising a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof.

According to another aspect of the present invention, a pharmaceutical composition for preventing or treating vaginitis is provided, comprising (i) a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof; and (ii) a pharmaceutically acceptable carrier.

The above vaginitis may be at least one disease selected from the group consisting of bacterial vaginosis, candida vaginitis, Trichomonas vaginitis, and atrophic vaginitis, and preferably bacterial vaginosis or candida vaginitis.

The term “prevention” in the present invention means inhibiting the occurrence of a disease, condition or symptom in an animal that has not been diagnosed as having a disease, condition or symptom due to the disease, condition or symptom, but is prone to such disease, condition or symptom.

The term “treatment” in the present invention means (i) inhibition of the development of a disease, condition or symptom, (ii) alleviation of a disease, condition or symptom, or (iii) elimination of a disease, condition or symptom.

Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are those commonly used in formulation, and include, but are not limited to, carbohydrate compounds (e.g., lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose, etc.), acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, salt solutions, alcohol, gum arabic, vegetable oils (e.g., corn oil, cottonseed oil, soy milk, olive oil, coconut oil), polyethylene glycol, methyl cellulose, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil.

The pharmaceutical composition of the present invention may further contain, in addition to the above components, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

The suitable dosage of the pharmaceutical composition of the present invention can be prescribed variously depending on factors such as the formulation method, administration method, patient's age, weight, sex, pathological condition, food, administration time, administration route, excretion rate, and reaction sensitivity. Meanwhile, the oral dosage of the pharmaceutical composition of the present invention is preferably 0.001 to 1000 mg/kg (body weight) per day.

The pharmaceutical composition of the present invention can be manufactured in a unit dose form or can be manufactured by introducing it into a multi-dose container by formulating it using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by a person having ordinary skill in the art to which the present invention pertains. At this time, the formulation may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granules, tablets or capsules, and may additionally contain a dispersant or stabilizer.

According to another aspect of the present invention, a food composition for preventing or improving vaginitis is provided, comprising a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof.

The food composition of the present invention can be manufactured as a functional food, a nutritional supplement, a health food, or a food additive, but is not limited thereto.

The food composition of the present invention can be manufactured in various forms according to conventional methods known in the art, and can be manufactured in the form of, for example, a beverage such as fermented milk, or a powder.

The food composition of the present invention contains not only the effective ingredient of the present invention described above, but also components commonly added during food manufacturing, such as proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. Examples of the carbohydrates described above include monosaccharides, such as glucose, fructose, etc.; disaccharides, such as maltose, sucrose, oligosaccharides, etc.; and polysaccharides, such as dextrin, cyclodextrin, etc., and conventional sugars and sugar alcohols, such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [thaumatin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.

When the food composition of the present invention is manufactured in the form of a beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, Eucommia extract, jujube extract, licorice extract, etc. may be additionally included in addition to the effective ingredient of the present invention.

According to another aspect of the present invention, a pharmaceutical composition for preventing or improving vaginitis is provided, comprising a composition comprising at least one selected from the group consisting of the strain, a dead cell thereof, and a culture thereof.

When the Lactobacillus rhamnosus CBT LR6-feminine strain of the present invention is used as an quasi-drug composition, the strain, its dead cells or its culture may be added as is or used together with other quasi-drug ingredients, and may be appropriately used according to a conventional method. The mixing amount of the effective ingredients may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). Preferably, the quasi-drug composition may be a disinfectant, shower foam, gargle, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.

Considering the complexity of this specification, the overlapping contents are identical to those described in other aspects of the present invention described above, and therefore, they are cited, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which the present invention belongs.

As described in detail above, the Lactobacillus rhamnosus CBT LR6-feminine strain of the present invention has excellent lactic acid production ability and hydrogen peroxide production ability, and has antibacterial activity against not only vaginitis-causing bacteria but also urinary tract infection-causing bacteria, and has excellent vaginal adhesiveness, acid resistance, and bile resistance. Therefore, it has been experimentally proven and confirmed that it can be effectively used for the prevention, alleviation, or treatment of vaginitis related to women's health.

Figure 1 shows the results of measuring the organic acid production ability of the control strain L. rhamnosus ATCC 7469 (LR type), L. rhamnosus LGG (LGG) strain, and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3).
Figure 2 shows the results of measuring the hydrogen peroxide production ability of the control strain L. rhamnosus ATCC 7469 (LR type), L. rhamnosus LGG (LGG) strain, and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3).
Figure 3 shows the results of measuring the inhibitory activity (antibacterial activity) against harmful bacteria of the control strain L. rhamnosus ATCC 7469 (LR type), L. rhamnosus LGG (LGG) strain, and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3).
Figure 4 shows the results of measuring the adhesive ability of harmful bacteria by co-aggregation assay of the control strain L. rhamnosus ATCC 7469 (LR type), L. rhamnosus LGG (LGG) strain, and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3).
Figure 5 shows the results of measuring the intravaginal adhesiveness of the control strain L. rhamnosus ATCC 7469 (LR type) and L. rhamnosus LGG (LGG) and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3) against the cervical cancer cell line HeLa by adhesion analysis.
Figure 6 shows the results of measuring the cultivability in acidic anaerobic conditions through acid resistance analysis of the control strain L. rhamnosus ATCC 7469 (LR type), L. rhamnosus LGG (LGG) strain, and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3).
Figure 7 shows the results of measuring the bile resistance of the control strain L. rhamnosus ATCC 7469 (LR type), L. rhamnosus LGG (LGG) strain, and three isolated strains ( L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, L. rhamnosus LR6-v3).

The specific embodiments described in this specification are meant to represent preferred embodiments or examples of the present invention, and the scope of the present invention is not limited thereby. It will be apparent to those skilled in the art that modifications and other uses of the present invention do not depart from the scope of the invention described in the claims of this specification.

Example 1: Isolation of strains derived from the vagina of healthy Korean women

Vaginal swab specimens from 20 healthy Korean volunteers (Nugent score 3 or lower) aged 19 to 50 years were received from the Department of Obstetrics and Gynecology, Konkuk University in 2022 using a vaginal swap kit (Noblebio, South Korea) under IRB review (KUMC 2022-04-030). The vaginal swab specimens were immediately cultured at 37°C in MRS culture medium (Difco) containing 0.01% sodium azide. After 24 hours of incubation, the cultured colony was subjected to 16S rDNA PCR using the primers 27F (5′-AGAGTTTGATCCTGGCTCAG-3′) and 1492R (5′-GGTTACCTTGTTAGACTT-3′) for strain identification. The base sequence of the 16S rRNA gene (16S rDNA) analyzed from the PCR product is the same as SEQ ID NO: 1, and it was identified as a Lactobacillus rhamnosus ( L. rhamnosus ) strain. Afterwards, three strains of L. rhamnosus were isolated and identified, and the strain names were named as L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, and L. rhamnosus LR6-v3, respectively.

Example 2: Strain and culture condition

The strains used as controls were Lactobacillus rhamnosus ( L. rhamnosus ) ATCC 7469, Lactobacillus rhamnosus ( L. rhamnosus ) LGG, and a total of five Lactobacillus rhamnosus ( L. rhamnosus ) strains, including three isolated strains, were used in the examples of the present invention, and all were cultured in MRS medium at 37°C for 18 hours. Candida albicans ( C. albicans ), the causative agent of Candida vaginitis, and Escherichia coli ( E. coli ), the causative agent of urinary tract infection, were cultured aerobically at 37°C for 18 hours using YPD and TSB media, respectively, and Gardnerella vaginalis ( G. vaginalis ), the causative agent of bacterial vaginosis, was cultured anaerobically at 37°C for 24 hours using TSB (k1-hemin solution) media.

Example 3: Measurement of acid producing ability

The genus Lactobacillus has the characteristic of producing a large amount of organic acids including lactic acid, which lowers the pH of the surrounding environment and inhibits the growth of surrounding pathogenic microorganisms. In particular, the vaginal environment is dominated by the genus Lactobacillus, so it is very important to maintain acidic conditions. To confirm the acid-producing ability of the isolated strains, each lactic acid bacteria was cultured at 37℃ using MRS medium. The cells in the culture solution were removed by centrifugation and sterilized without heat using a 0.45 μm filter. Afterwards, the concentrations of acetic acid, citric acid, and lactic acid in the culture filtrate were measured using HPLC (agilent). As a result, it was confirmed that the organic acid-producing ability of the isolated strain was statistically superior to that of the control strain (Fig. 1). In particular, the concentration of lactic acid was confirmed to be significantly higher in all three isolated strains (LR6-v1, LR6-v2, LR6-v3) compared to the control strains L. rhamnosus ATCC 7469 (LR type) and L. rhamnosus LGG (LGG) (Fig. 1).

Example 4: Measurement of hydrogen peroxide producing ability

Lactobacillus genus exhibits a wide range of antibacterial activity against not only bacteria but also viruses and yeast by producing hydrogen peroxide as well as acidification through organic acid production. To confirm the hydrogen peroxide production ability of the isolated strains, each lactic acid bacteria was cultured for 48 h under anaerobic conditions at 37℃ using TMB (1,3,5-trimethyl benzene)-MRS solid medium. After culturing, the cultures were exposed to aerobic conditions for 30 minutes to produce hydrogen peroxide, and then the color change of the colonies was observed. As a result, it was confirmed that all three isolated strains (LR6-v1, LR6-v2, LR6-v3) turned blue compared to the control group, L. rhamnosus ATCC 7469 (LR type). Based on this, it was confirmed that L. rhamnosus LR6-v1, L. rhamnosus LR6-v2, and L. rhamnosus LR6-v3 strains had excellent hydrogen peroxide production abilities (Fig. 2).

Example 5: Measurement of harmful bacteria inhibition ability (antibacterial activity)

To confirm the antibacterial activity of the control group and the isolated strains against vaginitis and urinary tract infection pathogens, C. albicans and G. vaginalis , which are vaginitis pathogens, and E. coli , which is a urinary tract infection pathogen, were inoculated into 96-well plates using YPD, LB, and TSB media, respectively, and the culture filtrates of Lactobacillus strains were treated and anaerobically cultured for 18 hours at 37℃. The growth inhibition ability against the harmful bacteria (vaginitis pathogens, urinary tract infection pathogens) was measured by measuring the absorbance at a wavelength of 600 nm. As a result, it was confirmed that the L. rhamnosus LR6-v3 strain had similar or superior harmful bacteria inhibition ability (antibacterial activity) compared to the control group, L. rhamnosus ATCC 7469 (LR type) or L. rhamnosus LGG (LGG) strain (Fig. 3).

Example 6: Measurement of harmful bacteria adhesion (co-aggregation assay)

The strains living in the vagina attach to the surface and live in colonies, but probiotics physically adsorb to them and inhibit their growth and attachment. Therefore, in order to confirm how well the control group and the isolated strains attach to harmful bacteria and function as probiotics, a co-aggregation assay was performed using C. albicans and G. vaginalis , which are causes of vaginitis, and E. coli , which is the cause of urinary tract infection. The harmful bacteria (causative bacteria of vaginitis and urinary tract infection) and Lactobacillus strains were each adjusted to have an absorbance of 1 at 600 nm to make the cell ratio the same, then washed twice with PBS and re-inoculated together in PBS and reacted for 24 hours under 37℃ conditions. After collecting 1 mL of the upper part of the PBS strain suspension, the absorbance was measured at 600 nm again, and the co-aggregation ratio was calculated as the difference before and after the reaction. As a result, all three isolated strains (v1, v2, v3) were found to have superior adhesive ability to the causative bacteria of vaginitis and urinary tract infection compared to the control strains , L. rhamnosus ATCC 7469 (type) or L. rhamnosus LGG (LGG) (Fig. 4).

Example 7: Measurement of adhesion in the vagina (cell adhesion assay)

To confirm the cell adhesion ability of the control and isolated strains to the cervical cancer cell line HeLa, HeLa cells were seeded at 5 X 10 ⁴ cells/well and cultured in an incubator at 37°C, 5% CO ₂ for 48 hours, and then washed twice with PBS. 500 μL of the control and isolated strain suspensions (2 X 10 ⁸ cfu/mL) were added to each well, and then cultured at 37°C for 1 hour. The cultured HeLa cells were washed with sterile PBS, and then the HeLa cells were detached from the plate with sterile distilled water. In order to measure the number of viable cells of the control and isolated strains attached to the above-mentioned surviving cells, the strains were inoculated onto MRS solid medium and cultured in an incubator at 37℃ for 24 hours. The cultured strains were counted using the colony counting method. As a result, it was confirmed that L. rhamnosus LR6-v2 and L. rhamnosus LR6-v3 strains attached to cervical cancer cells statistically significantly better than the control strains, L. rhamnosus ATCC 7469 (LR type) and L. rhamnosus LGG (LGG) (Fig. 5).

Example 8: Measurement of culturability in acidic anaerobic conditions (acid tolerance assay)

The vaginal environment is usually anaerobic and has an acidic pH of 4 to 5.5, which is an environment in which it is difficult for strains to grow. Therefore, the difference in strain cultivability under these acidic anaerobic conditions can be a very important requirement after settlement. In order to confirm the acid resistance of the control group and the isolated strain, the MRS medium, a lactic acid bacteria culture medium, was adjusted according to pH and cultured. The culture medium was adjusted to pH 3, 4, 5, and 6, and cultured at 37°C under anaerobic conditions for 18 hours. After the culture was completed, the absorbance was measured using a wavelength of 595 nm, and the analysis results are shown in Fig. 6. As a result, under pH 3 conditions, all strains showed growth inhibition of about 0.2 OD values without much difference, but under pH 4 conditions, L. rhamnosus LR6-v2 and L. rhamnosus LR6-v3 strains showed significantly better acid resistance than L. rhamnosus ATCC 7469 (LR type) strain, and L. rhamnosus LR6-v3 strain showed significantly better acid resistance than L. rhamnosus LGG (LGG) strain. Under pH 5 conditions, L. rhamnosus LR6-v1, LR6-v2, and LR6-v3 strains showed significantly better acid resistance than L. rhamnosus ATCC 7469 (LR type) and L. rhamnosus LGG (LGG) strains. In addition, under pH 6 conditions, L. rhamnosus LR6-v3 strain was confirmed to have the best acid resistance.

Example 9: Measurement of Bile Acid Tolerance

To confirm the bile resistance of the control group and the isolated strain, 0.3% or 0.5% oxgall was added to MRS, a lactic acid bacteria culture medium, and cultured for 4 hours under anaerobic conditions at 37℃. After culture was completed, the solution was diluted and inoculated onto MRS solid medium, and cultured again for 24 hours under the same conditions, and the number of viable cells was measured to analyze the bile resistance (Fig. 7). As a result, in the medium supplemented with 0.5% oxgall, the survival rates (bile tolerance) of another control strain L. rhamnosus LGG (LGG) and three isolated strains ( L. rhamnosus LR6-v1, LR6-v2, and LR6-v3) were all lower than those of the control strain L. rhamnosus ATCC 7469 (LR type). However, in the medium supplemented with 0.3% oxgall, it was confirmed that another control strain L. rhamnosus LGG (LGG) and the isolated strain L. rhamnosus LR6-v3 together showed superior survival rates (bile tolerance) than those of the control strain L. rhamnosus ATCC 7469 (LR type).

While the specific parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred implementation examples and that the scope of the present invention is not limited thereto. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Korea Research Institute of Bioscience and Biotechnology KCTC19091P 20230515

Attach electronic file of sequence list

Claims (8)

Lactobacillus rhamnosus CBT LR6-feminine strain deposited under the accession number KCTC19091P.
In the first paragraph,
A strain characterized in that the strain comprises a 16S rRNA gene represented by sequence number 1.
In the first paragraph,
The strain is characterized in that it has antibacterial activity against Candida albicans, Gardnerella vaginalis or Escherichia coli .
A composition comprising at least one selected from the group consisting of a strain according to any one of claims 1 to 3, a dead cell thereof, and a culture thereof.
An antibacterial composition comprising a composition according to claim 4.
(i) a composition according to paragraph 4; and (ii) a pharmaceutical composition for preventing or treating vaginitis, comprising a pharmaceutically acceptable carrier.
A food composition for preventing or improving vaginitis, comprising a composition according to Article 4.
A pharmaceutical composition for preventing or improving vaginitis, comprising a composition according to Article 4.